UNSPSC 51382602: Lotifazole

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C12H9Cl3N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1B3TF200TI, chemically known as 2,2,2-trichloroethyl (4-phenyl-2-thiazolyl)carbamate but generally known as lotifazole, which bears US NIH Compound Identifier 68905. European Medicines Agency schedules Lotifazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08600MIG.

UNSPSC 51382602 Lotifazole, a Commodity-level code, shows minimal direct alignment with recent state and local procurement activity. The three recent opportunities tagged to this code—Seminole County's IFB for naloxone and drug deactivation systems, the Texas Health and Human Services Commission's RFI on direct-to-manufacturer pharmacy programs, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products—represent broader pharmaceutical procurement, community health supplies, and pharmacy benefit management rather than lotifazole specifically. The actual scope of work across these opportunities spans naloxone distribution for opioid response, pharmacy benefit program structure and direct contracting, and generic pharmaceutical supply agreements serving multiple state and local health facilities. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas HHS Commission), and multistate cooperative purchasing vehicles (MMCAP, administered by Minnesota Department of Administration). None of the recent solicitations explicitly names lotifazole as a product line item.

Geographic activity concentrates in Florida, Texas, and Minnesota, with MMCAP's multi-state reach including Oregon. The Seminole County IFB (IFB60459723LAS, response deadline July 26, 2023) is the only recent opportunity directly naming a specific pharmaceutical product procurement—1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries. The Texas HHS RFI (HHS0017013, posted April 3, 2026) is exploratory market intelligence on direct-to-manufacturer pharmacy contracting and does not yet commit to specific product procurement. The MMCAP RFP (S1070000015802, response deadline March 26, 2026) establishes multi-vendor contracts for generic pharmaceuticals and OTC products effective July 1, 2026, distributed through three authorized wholesalers. The code shows limited evidence of direct lotifazole procurement in recent state and local activity.